专题:Psoriasis: Treatment and Pathogenesis

This cluster of papers focuses on the reciprocal developmental pathways for the generation of pathogenic effector TH17 cells and regulatory T cells, particularly in the context of autoimmune inflammation, interleukin-23, psoriasis, and the role of cytokines such as TGF-ß. It also explores the differentiation, cytokine profile, and function of human interleukin 17–producing helper T cells.
最新文献
近5年高被引文献
IL-17 and IL-17-producing cells in protection versus pathology

review Full Text OpenAlex 908 FWCI68.6082

Advances in the pathogenesis of psoriasis: from keratinocyte perspective

review Full Text OpenAlex 577 FWCI44.2331

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021

review Full Text OpenAlex 568 FWCI88.0885

Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach

review Full Text OpenAlex 475 FWCI44.5381

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

article Full Text OpenAlex 373 FWCI64.8799

The IL-17 family in diseases: from bench to bedside

review Full Text OpenAlex 373 FWCI59.2013

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

article Full Text OpenAlex 333 FWCI25.5689

Signaling pathways and targeted therapies for psoriasis

review Full Text OpenAlex 326 FWCI51.8174

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update

review Full Text OpenAlex 304 FWCI126.7732

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

article Full Text OpenAlex 303 FWCI52.2022